Products and Services

Perceptronix’ products and services offer an improvement over existing cancer detection technologies and provide physicians with increased options for prolonging and improving the quality of patients’ lives. 

The company has developed two innovative, cancer diagnostic technologies based on image cytometry that have received Health Canada and the EU Directive (CE mark) regulatory approvals:

1. ClearSign™¹ – Measures chromatin changes in normal appearing epithelial cells from sputum samples and is used in predictive and risk assessment medicine
2. ClearCyte™²– Assists in finding gross DNA abnormalities of diagnostic and prognostic value in any cytological specimen

Perceptronix has developed three tests based on these technology platforms and offers them from its Clinical Quantitative Cytology Laboratory:

1. LungSign™³ Test for early lung cancer detection
2. OralAdvance™⁴ Test for early oral cancer detection
3. ClearCyte™ Test for cancer diagnosis and prognosis using any liquid-based cytological specimen

LungSign™ – Lung Cancer Risk Assessment

LungSign™ is a safe, painless and convenient test to assess risk of lung cancer. It is based on an innovative marker in sputum that is highly correlated with the presence of lung malignancy - even in early stage disease. LungSign™ is the first test to market that provides both an independent result to help with the early detection of lung cancer and a useful complement to current radiological diagnostic methods.

For more information please see www.LungSign.com.

OralAdvance™ – Oral Cancer Quantitative Cytology Test

OralAdvance™ is a highly specific and sensitive test for the early detection of oral cancer, utilizing advanced cytometry technology (ClearCyte™) and expert cytopathology assessment to detect DNA abnormalities.

OralAdvance™ utilizes a soft cyto-brush kit to collect buccal mucosa from suspect areas and standardized liquid-based cytology preparation coupled with innovative DNA cytometry analysis in order to provide dentists with a more consistent and accurate cancer cytology service.

For more information please see www.OralAdvance.com.

ClearCyte™ – Advanced Cytopathology

ClearCyte™ based tests utilize advanced cytometry technology and expert cytopathology assessment resulting in increased diagnostic sensitivity (compared with conventional cytology) and important new prognostic information (DNA ploidy) for patient treatment and follow-up.

Utilizing intelligent proprietary automated image cytometry technology, ClearCyte™ captures, measures and sorts imaged cell nuclei according to DNA ploidy and other nuclear features. The presence of an abnormal DNA content (aneuploidy) reflects extensive DNA changes (gross genomic aberrations) usually indicating the presence of malignancy, correlating with tumor progression and poor survival.

ClearCyte™ can be applied to any cytological specimen.

To order, Contact Us.

Clear2C^®5 – Quantitative Staining Kit

Clear2C^® is a Quantitative DNA Staining Kit delivering cost-effective, convenient, repeatable and reliable DNA staining for absorbance microscopy at a competitive price.

Clear2C^® is currently sold to research and clinical laboratories performing quantitative DNA measurements using image cytometry. While optimized for DNA quantification with ClearCyte™, it may also be effectively used with other cytometry platforms.

To order, Contact Us.

¹ ClearSign™ is a medical device licensed in accordance with the Food and Drugs Act (Canada) license number 72090 and has the European CE Mark – EU Directive 98/79/EC. ClearSign™ is licensed for sale within Canada and the EU.
² ClearCyte™ is a medical device licensed in accordance with the Food and Drugs Act (Canada) license number 70362 and has the European CE Mark – EU Directive 98/79/EC. ClearCyte™ is licensed for sale within Canada and the EU.
³ LungSign™ utilizes both ClearSign™ and ClearCyte™ technology.
⁴ OralAdvance™ utilizes ClearCyte™ technology.
⁵ Clear2C^® is a medical device licensed in accordance with the Food and Drugs Act (Canada) license number 70361, has the European CE Mark – EU Directive 98/79/EC, and is a FDA registered medical device. Clear2C^® is licensed for sale within Canada, the EU, and the USA.